Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Soticlestat - Takeda

Next Previous
Drug Profile

Soticlestat - Takeda

Alternative Names: OV-935; TAK 935

Latest Information Update: 10 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class Analgesics; Antiepileptic drugs; Heterocyclic compounds; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Cholesterol 24-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Complex regional pain syndromes; Dravet syndrome; Lennox-Gastaut syndrome

Most Recent Events

  • 10 Feb 2025 Discontinued - Phase-II for Complex regional pain syndromes (Adjunctive treatment) in United Kingdom (PO) prior to February 2025 (Takeda Pipeline, February 2025)
  • 10 Feb 2025 Discontinued - Phase-II for Dravet syndrome (In adolescents, In children, Adjunctive treatment, In adults) in Portugal (PO) prior to February 2025 (Takeda Pipeline, February 2025)
  • 10 Feb 2025 Discontinued - Phase-II for Dravet syndrome (In adults, Adjunctive treatment, In children, In adolescents) in Israel (PO) prior to February 2025 (Takeda Pipeline, February 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top